May 19, 2017 08:34 AM EDT
R&D
Pharma

The EMA re­jects XBiotech’s can­cer drug af­ter an em­bar­rass­ing PhI­II — but they’re not giv­ing up

Shehla Shakoor

Managing Director

You can file this sto­ry in the Not Sur­prised fold­er.

Austin-based XBiotech’s ap­pli­ca­tion to start sell­ing its lead can­cer ther­a­py has been spurned by …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times